Theraclion has announced interim clinical results on a crucial innovation, Beamotion, to speed up EchoPulse therapy five times. The CE-marked EchoPulse device precisely focuses high-energy sound to break down benign but troublesome breast fibroadenomas and palpable thyroid nodules. EchoPulse is easy to use and leaves no scars, with no infection or surgical risks. US trials have started. In H115, Theraclion gained three new orders, had revenues of €56k, a reported loss of €3.2m and c
02 Nov 2015
Faster treatment opens market
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Faster treatment opens market
Theraclion has announced interim clinical results on a crucial innovation, Beamotion, to speed up EchoPulse therapy five times. The CE-marked EchoPulse device precisely focuses high-energy sound to break down benign but troublesome breast fibroadenomas and palpable thyroid nodules. EchoPulse is easy to use and leaves no scars, with no infection or surgical risks. US trials have started. In H115, Theraclion gained three new orders, had revenues of €56k, a reported loss of €3.2m and c